(Q33504586)

27 July 2017

Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study (English)

1 reference

27 July 2017

D Lüftner

1

1 reference

27 July 2017

B Flath

2

1 reference

27 July 2017

C Akrivakis

3

1 reference

27 July 2017

H G Mergenthaler

4

1 reference

27 July 2017

U Ohnmacht

5

1 reference

27 July 2017

M Arning

6

1 reference

27 July 2017

K Possinger

7

1 reference

27 July 2017

1 January 1998

1 reference

Investigational New Drugs

27 July 2017

1 reference

27 July 2017

16

1 reference

27 July 2017

141-146

1 reference

27 July 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1006121608414

27 July 2017

0 references

cites work

FEC (5-fluorouracil-epirubicin-cyclophosphamide) monthly versus FEC weekly in metastatic breast cancer. First results of a randomized trial

1 reference

12 December 2020

Cancer in the European community and its member states

1 reference

12 December 2020

Advanced breast cancer: a phase II trial with gemcitabine

1 reference

12 December 2020

Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1006121608414

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference